Effect of local treatment with adipose tissue-derived mesenchymal stem cells in the early tumorigenesis of osteosarcoma

Lee,Sheen-Woo; Jeon,Tae Joo; Biswal,Sandip

doi:10.3892/or.2015.3711

Effect of local treatment with adipose tissue-derived mesenchymal stem cells in the early tumorigenesis of osteosarcoma

Authors:
- Sheen-Woo Lee
- Tae Joo Jeon
- Sandip Biswal
View Affiliations

Affiliations: Department of Radiology, Gil Hospital, Gachon University School of Medicine and Science, Incheon 406‑799, Republic of Korea, Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, Republic of Korea, Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305-5105, USA
Published online on: January 8, 2015 https://doi.org/10.3892/or.2015.3711
Pages: 1381-1387

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There are conflicting data describing the effect of mesenchymal stem cells (MSCs) on tumorigenesis. The present study aimed to determine the survival rate and effect of adipose tissue-derived MSCs (ADMSCs) in tumor growth using bioluminescence imaging (BLI) and ultrasound (US) in an osteosarcoma xenograft model. Firefly luciferase-expressing ADMSCs combined with the osteosarcoma cell line UMR-106 in 4 different proportions (5, 10, 15 and 25%, named G1-G4, respectively) were xenografted into the right flanks of nude mice. The same number of UMR-106 cells was inoculated into the contralateral side of each mouse. Serial bioluminescence images were captured over 16 days to monitor the presence of ADMSCs in each group of 5 animals. The tumor volume was measured by ultra-high resolution US, and the tumor volume ratio (AMDSC mixed xenograft/control xenograft) was obtained to evaluate the effect of AMDSCs on tumor growth. Immunohistochemistry was performed to confirm the distribution of residual AMDSCs in the tumor. In G1, G2 and G3, the suppression of tumor growth by AMDSCs was noted in 2/5, 4/5 and 4/5 mice, respectively. However, accelerated tumor growth was noted in G4, which had the highest proportion of ADMSCs. The tumor volume ratio was significantly lower in G2 and G3 compared to G4, by Mann-Whitney U test (P=0.0159). Bioluminescence images demonstrated a serial decrement of the reporter gene for ADMSCs in the tumor mass without evidence of proliferation. Immunohistochemistry staining revealed minimal residual ADMSCs in the tumor periphery. Taken together, our data revealed that direct inoculation of ADMSCs into a tumor xenograft caused the death of the majority of ADMSCs in the tumor mass. Furthermore, relatively low proportions of ADMSCs suppressed the growth of osteosarcoma, while higher proportions showed a tumor-promoting effect.

View Figures

View References

1	Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al: Embryonic stem cell lines derived from human blastocysts. Science. 282:1145–1147. 1998. View Article : Google Scholar : PubMed/NCBI
2	Wagner AM, Krenger W, Holzgreve W, Burkle P and Surbek DV: Use of human embryonic stem cells and umbilical cord blood stem cells for research and therapy: a prospective survey among health care professionals and patients in Switzerland. Transfusion. 53:2681–2689. 2013. View Article : Google Scholar : PubMed/NCBI
3	Faulkner SD, Vawda R and Fehlings MG: Adult-derived pluripotent stem cells. World Neurosurg. 82:500–508. 2014. View Article : Google Scholar
4	Cao F, Lin S, Xie X, et al: In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation. 113:1005–1014. 2006. View Article : Google Scholar : PubMed/NCBI
5	Serakinci N, Christensen R, Fahrioglu U, et al: Mesenchymal stem cells as therapeutic delivery vehicles targeting tumor stroma. Cancer Biother Radiopharm. 26:767–773. 2011. View Article : Google Scholar : PubMed/NCBI
6	Nakamizo A, Marini F, Amano T, et al: Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 65:3307–3318. 2005.PubMed/NCBI
7	Khakoo AY, Pati S, Anderson SA, et al: Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med. 203:1235–1247. 2006. View Article : Google Scholar : PubMed/NCBI
8	Qiao L, Xu Z, Zhao T, et al: Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res. 18:500–507. 2008. View Article : Google Scholar : PubMed/NCBI
9	Katsuno T, Ochi M, Tominaga K, et al: Mesenchymal stem cells administered in the early phase of tumorigenesis inhibit colorectal tumor development in rats. J Clin Biochem Nutr. 53:170–175. 2013. View Article : Google Scholar : PubMed/NCBI
10	Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 62:3603–3608. 2002.PubMed/NCBI
11	Zhu W, Xu W, Jiang R, et al: Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol. 80:267–274. 2006. View Article : Google Scholar
12	Djouad F, Plence P, Bony C, et al: Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 102:3837–3844. 2003. View Article : Google Scholar : PubMed/NCBI
13	Studeny M, Marini FC, Dembinski JL, et al: Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 96:1593–1603. 2004. View Article : Google Scholar : PubMed/NCBI
14	Davidoff AM, Ng CY, Brown P, et al: Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res. 7:2870–2879. 2001.PubMed/NCBI
15	Patel SA, Heinrich AC, Reddy BY, Srinivas B, Heidaran N and Rameshwar P: Breast cancer biology: the multifaceted roles of mesenchymal stem cells. J Oncol. 2008:4258952008. View Article : Google Scholar : PubMed/NCBI
16	Dwyer RM, Khan S, Barry FP, O’Brien T and Kerin MJ: Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther. 1:252010. View Article : Google Scholar : PubMed/NCBI
17	Schäffler A and Büchler C: Concise review: adipose tissue-derived stromal cells - basic and clinical implications for novel cell-based therapies. Stem Cells. 25:818–827. 2007. View Article : Google Scholar
18	Zhao W, Ren G, Zhang L, et al: Efficacy of mesenchymal stem cells derived from human adipose tissue in inhibition of hepatocellular carcinoma cells in vitro. Cancer Biother Radiopharm. 27:606–613. 2012. View Article : Google Scholar : PubMed/NCBI
19	Barry FP and Murphy JM: Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 36:568–584. 2004. View Article : Google Scholar : PubMed/NCBI
20	Zuk PA, Zhu M, Ashjian P, et al: Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 13:4279–4295. 2002. View Article : Google Scholar : PubMed/NCBI
21	Preston SL, Alison MR, Forbes SJ, Direkze NC, Poulsom R and Wright NA: The new stem cell biology: something for everyone. Mol Pathol. 56:86–96. 2003. View Article : Google Scholar : PubMed/NCBI
22	Lyden D, Hattori K, Dias S, et al: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 7:1194–1201. 2001. View Article : Google Scholar : PubMed/NCBI
23	Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D and Dazzi F: Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia. 21:304–310. 2007. View Article : Google Scholar
24	Sato T, Sakai T, Noguchi Y, Takita M, Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol. 92:47–56. 2004. View Article : Google Scholar : PubMed/NCBI
25	Ohlsson LB, Varas L, Kjellman C, Edvardsen K and Lindvall M: Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp Mol Pathol. 75:248–255. 2003. View Article : Google Scholar : PubMed/NCBI
26	Nakamura K, Ito Y, Kawano Y, et al: Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 11:1155–1164. 2004. View Article : Google Scholar : PubMed/NCBI
27	Wu GD, Nolta JA, Jin YS, et al: Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation. 75:679–685. 2003. View Article : Google Scholar : PubMed/NCBI
28	Barbash IM, Chouraqui P, Baron J, et al: Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 108:863–868. 2003. View Article : Google Scholar : PubMed/NCBI
29	Serakinci N, Fahrioglu U and Christensen R: Mesenchymal stem cells, cancer challenges and new directions. Eur J Cancer. 50:1522–1530. 2014. View Article : Google Scholar : PubMed/NCBI
30	Ghannam S, Bouffi C, Djouad F, Jorgensen C and Noel D: Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther. 1:22010. View Article : Google Scholar : PubMed/NCBI